Related Experiment Videos
Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas
1Department of Dermatology, University of Vienna Medical School, University of Vienna, Austria. robert.knobler@akh-wien.ac.at
Annals of the New York Academy of Sciences
|October 12, 2001
Summary
Extracorporeal photochemotherapy (ECP) treats T cell lymphoma by inducing apoptosis in diseased cells and converting monocytes to dendritic cells. These dendritic cells then present antigens to initiate anti-cancer responses or suppress autoimmune reactions.
Area of Science:
- Immunology
- Dermatology
- Oncology
Background:
- Extracorporeal photochemotherapy (ECP) is an established treatment for cutaneous T cell lymphoma (CTCL) and other T cell-mediated disorders.
- Despite extensive clinical use, the precise mechanisms underlying ECP's efficacy have remained largely unelucidated until recently.
- Advances in understanding T cell receptors, MHC antigen presentation, tumor antigens, dendritic cell biology, and immunopharmacology have paved the way for mechanistic insights.
Purpose of the Study:
- To review clinical trials of ECP in CTCL.
- To elucidate the evolving scientific understanding of ECP's mechanism of action.
- To explore future research directions for ECP in CTCL treatment.
Main Methods:
- Review of clinical trial data for ECP in CTCL.
- Analysis of recent scientific advancements relevant to ECP's mechanism.
- Synthesis of current knowledge on ECP's cellular and molecular effects.
Main Results:
- ECP induces apoptosis in pathogenic T cells and promotes the differentiation of monocytes into functional dendritic cells (DCs).
- These DCs process and present unique antigenic determinants from malignant T cells.
- This presentation can elicit a cytotoxic T cell response against CTCL or suppress autoreactive T cells in other disorders.
Conclusions:
- ECP's efficacy is attributed to its dual action on T cells and dendritic cells.
- The generated DCs play a crucial role in either initiating anti-tumor immunity or immune suppression.
- Further research into ECP's mechanisms holds promise for optimizing its application and developing novel immunotherapies.